Selective toxicity of deoxyadenosine analogues in human melanoma cell lines.
The in vitro toxicities of 19 analogues of deoxyadenosine were tested using a panel of human melanoma cell lines including two lines sensitive to deoxyadenosine and deoxyinosine. The 2-fluoro-, 2-chloro-, 2-bromo- and 2-amino-8-aza derivatives were the most toxic and showed selectivity against deoxyadenosine-sensitive cells. 2-Bromodeoxyadenosine (BrdAdo) and its 5'-phosphate were less potent than the chloro compound but showed the greatest selectivity. In further studies of BrdAdo a third sensitive melanoma line was identified of the eight tested. A treatment time of 24 hr or more was required to develop toxicity to BrAdo; this could be prevented by deoxycytidine or cytidine added to the medium but not by other nucleosides. Flow cytometry showed that BrdAdo blocked cells in the G1 and S phases of the cell cycle. DNA synthesis as judged by thymidine incorporation was rapidly inhibited by BrdAdo to an extent which reflected the sensitivity of the particular cell line; RNA synthesis was less affected. Exposure to BrdAdo for 48 hr induced breaks in the preformed DNA of sensitive but not resistant cells. The results suggest that the toxicity of BrdAdo is associated with prolonged inhibition of DNA synthesis and subsequent DNA fragmentation.
D002453:Cell Cycle / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D004249:DNA Damage; D003839:Deoxyadenosines / Q000031:analogs & derivatives / Q000494:pharmacology*; D006367:HeLa Cells / Q000187:drug effects; D006801:Humans; D008545:Melanoma / Q000473:pathology*; D012313:RNA / Q000096:biosynthesis; D013329:Structure-Activity Relationship
D003839:Deoxyadenosines; D012313:RNA; C036855:2'-bromo-2'-deoxyadenosine; D004247:DNA